Conference Coverage
Latest News
Jul 07, 2026 | News
Why Do Some Psoriasis Patients Respond Differently to Biologics? New Study Offers Clues
Teva Advances TEV-'408 Into Phase 2b for Vitiligo
Jul 07, 2026
Smoking Associated with Increased Nail Psoriasis Severity, Case-Control Study Finds
Jul 07, 2026
GX-03 Phase 2 Program Expands to Full Atopic Dermatitis Spectrum
Jul 07, 2026
Clinicians Weigh Immunotherapy Selection and Referral Roles in Advanced CSCC
Jul 06, 2026
Videos
Advertisement
Shorts
0:24
Why patients are moving away from injectable psoriasis treatments
19 hours ago
by
Linda Stein Gold, MD
1:10
A Win for Patients and Providers: Roflumilast’s Expanded PsO Indication
6 days ago
by
Christopher G. Bunick, MD, PhD
1:00
Roflumilast Cream Approved for Children as Young as 2 With Plaque Psoriasis
7 days ago
by
Jennifer Soung, MD
0:28
Rethinking First-Line Treatment for Atopic Dermatitis
11 days ago
by
David Cotter, MD, PhD
2:18
What AbbVie’s Acquisition of Apogee Means for AD Treatment
11 days ago
by
Christopher G. Bunick, MD, PhD
0:42
When Patients Fear Their AD Medication
12 days ago
by
Mona Shahriari, MD, FAAD
0:35
The Myths Surrounding Food Allergies and Atopic Dermatitis
13 days ago
by
Jennifer Soung, MD
0:59
Why Chronic Hand Eczema is More Than Just an Itch
18 days ago
by
David Rosmarin, MD
0:16
Why Individualized Care Matters in the Age of "Preventative Botox"
21 days ago
by
Shawna Jones, PA-C
0:36
Expanding Access and Promoting Purpose in Dermatology
22 days ago
by
Amy Snow, PA-C
GEP-Guided Treatment for Melanoma & SCC Management
New Insights in Management of Moderate Hidradenitis Suppurativa
Discover Dermatology Times NP/PA Connect™!
Personalizing Treatment for Difficult Atopic Dermatitis Cases
Connect With Dermatology Times® Wherever You Scroll
Podcasts
Dermatology Times Digital Edition
Learn more about the in-depth topics covered in the June 2026 print issue of Dermatology Times.
Lim considers mentoring and helping develop the next generation of dermatologists one of his most meaningful contributions to the specialty.
Andrew Krakowski, MD, encourages involving both caregivers and children in treatment decisions, giving young patients a sense of ownership that can significantly improve adherence.
New data show that nearly two-thirds of Sun Bus participants had never visited a dermatologist, highlighting persistent gaps in access to skin cancer care.
Career decisions in dermatology are too often driven by emotion rather than data, according to a new practice management column examining common pitfalls in contract evaluation and compensation negotiations.
Innovations in packaging, formulation design, and alternative preservation strategies may reduce preservative concentrations, but they are unlikely to eliminate the need for preservatives entirely.
Data from the BroADen trial suggest that targeting STAT6 through protein degradation may offer a novel oral approach to controlling type 2 inflammation in atopic dermatitis.
Because BCC and cSCC have high tumor mutational burdens driven by UV-induced DNA damage, they are particularly well suited to immune checkpoint inhibition.
In clinical practice, digital twins could predict how individual patients respond to treatments based on factors such as genetics, skin barrier function, and lifestyle patterns.
A phase 2 clinical trial found that topical ruxolitinib cream showed promising efficacy and safety in patients with mild to moderate hidradenitis suppurativa.
Continuing Medical Education
All News
Advertisement
Advertisement
Can-Fite completed interim enrollment for its pivotal phase 3 trial of first-in-class oral A3AR agonist piclidenoson, a potential new mechanism for plaque psoriasis.
Explore top dermatology conferences and meetings in July 2026 and let us know which ones you'll be attending!
One-year phase 3 VELA data showed durable clinical responses, quality-of-life improvements, and no new safety signals for investigational sonelokimab in hidradenitis suppurativa.
Explore the top headlines of the month, including insights on the latest clinical trials, therapeutic updates, and more.
AbbVie's upadacitinib received a positive CHMP opinion for severe alopecia areata as FDA review continues in the US.
Learn more about the in-depth topics covered in the June 2026 print issue of Dermatology Times.
The approval expands the existing indication for adults and children down to age 6, includes intertriginous areas, and removes restrictions on duration of use.
Dermatology Times is looking back on the top stories in dermatology from the month of June.
Evommune's EVO756 failed to meet the primary end point in a phase 2b trial for chronic spontaneous urticaria, prompting the company to discontinue development for the indication while continuing studies in atopic dermatitis.
Despite often being highly treatable, nonmelanoma skin cancers account for millions of biopsies, procedures, and follow-up visits annually, creating a substantial healthcare burden.
Advertisement
Do nighttime collagen masks actually work or is it just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.
The FDA has accepted Replimune's third resubmitted BLA for RP1 plus nivolumab in advanced melanoma, setting an August 2 PDUFA date.
An Evolving Paradigms event led by Darrell S. Rigel, MD, MS, compared PD-1/PD-L1 immunotherapies for advanced cutaneous squamous cell carcinoma, with referral guidance and toxicity alerts.
Lim considers mentoring and helping develop the next generation of dermatologists one of his most meaningful contributions to the specialty.
Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of June.
Advertisement
Advertisement
Trending on Dermatology Times
1
GX-03 Phase 2 Program Expands to Full Atopic Dermatitis Spectrum
2
Guselkumab APEX Trial Supports New Joint Damage Label
3
First-in-Class Oral Piclidenoson Reaches Pivotal Phase 3 Enrollment Milestone in Plaque Psoriasis
4
Once-Daily Zasocitinib Offers New Oral Option for Psoriasis
5